Literature DB >> 16380082

Single-point mutations of hepatitis C virus NS3 that impair p53 interaction and anti-apoptotic activity of NS3.

Motofumi Tanaka1, Motoko Nagano-Fujii, Lin Deng, Satoshi Ishido, Kiyonao Sada, Hak Hotta.   

Abstract

The N-terminal domain of NS3 of hepatitis C virus (HCV) possesses serine protease activity, which is essential for virus replication. This portion is also implicated in malignant transformation of hepatocytes. We previously demonstrated that an N-terminal portion of NS3 formed a complex with the tumor suppressor p53 and suppressed actinomycin D-induced apoptosis. We report here that single-point mutations of NS3 at position 106 from Leu to Ala (L106A), and position 43 from Phe to Ala (F43A) to a lesser extent, significantly impaired complex formation with p53. Moreover, the L106A mutation impaired an otherwise more distinct anti-apoptotic activity of NS3. F43A and L106A mutations also inhibited serine protease activity of NS3. These results collectively suggest the possibility that Leu106 and Phe43 are involved in p53 interaction and serine protease activity, and therefore, can be a good target for certain low-molecular-weight compound(s) to inhibit both oncogenic and replicative abilities of HCV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380082     DOI: 10.1016/j.bbrc.2005.12.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer.

Authors:  D R McGivern; S M Lemon
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

Review 2.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

3.  Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway.

Authors:  Lin Deng; Tetsuya Adachi; Kikumi Kitayama; Yasuaki Bungyoku; Sohei Kitazawa; Satoshi Ishido; Ikuo Shoji; Hak Hotta
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

4.  Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR.

Authors:  Lu Peng; Dongyu Liang; Wenyan Tong; Jianhua Li; Zhenghong Yuan
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

Review 5.  Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases.

Authors:  Po-Yuan Ke; Steve S-L Chen
Journal:  Viruses       Date:  2012-10-19       Impact factor: 5.048

6.  Hepatitis C virus and hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Osamu Yokosuka; Masao Omata
Journal:  Biology (Basel)       Date:  2013-01-30

Review 7.  Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response.

Authors:  Srikanta Dash; Srinivas Chava; Yucel Aydin; Partha K Chandra; Pauline Ferraris; Weina Chen; Luis A Balart; Tong Wu; Robert F Garry
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

8.  Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity.

Authors:  Surasak Jittavisutthikul; Watee Seesuay; Jeeraphong Thanongsaksrikul; Kanyarat Thueng-In; Potjanee Srimanote; Rolf G Werner; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2016-08-26       Impact factor: 7.561

9.  Modulation of Cell Death Pathways by Hepatitis C Virus Proteins in Huh7.5 Hepatoma Cells.

Authors:  Olga V Masalova; Ekaterina I Lesnova; Pavel N Solyev; Natalia F Zakirova; Vladimir S Prassolov; Sergey N Kochetkov; Alexander V Ivanov; Alla A Kushch
Journal:  Int J Mol Sci       Date:  2017-11-06       Impact factor: 5.923

Review 10.  Oncogenic Signaling Induced by HCV Infection.

Authors:  Alessia Virzì; Armando Andres Roca Suarez; Thomas F Baumert; Joachim Lupberger
Journal:  Viruses       Date:  2018-10-02       Impact factor: 5.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.